News

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...
MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.